Previous 10 | Next 10 |
WATERTOWN, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:...
2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% . Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is one of today's top gainers. The company's shares are currently up 32.75% on the day to $7.54. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the Unit...
2023-04-21 10:03:36 ET Gainers: EyePoint Pharmaceuticals ( EYPT ) +19% . Tenaya Therapeutics ( TNYA ) +21% . Community Health Systems ( CYH ) +11% . NovaBay Pharmaceuticals ( NBY ) +11% . Aziyo Biologics ( AZYO ) +8% . Loser...
2023-04-20 17:51:34 ET Gainers: ContextLogic ( WISH ) +28% . EyePoint Pharmaceuticals ( EYPT ) +7% . Caribou Biosciences ( CRBU ) +5% . Ocular Therapeutix ( OCUL ) +3% . Coherus BioSciences ( CHRS ) +3% . Losers: CRISPR T...
- Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing ...
- Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retinal disease - - Clinical outcomes from real-world CALM registry study of YUTIQ ® ...
Gainers: A-Mark Precious Metals ( AMRK ) +6% . Absci ( ABSI ) +5% . Verve Therapeutics ( VERV ) +5% . Coherus BioSciences ( CHRS ) +5% . SouthState ( SSB ) +4% . Losers: Cytek Biosciences ( CTKB ) -12% . 2U ...
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2022 Earnings Conference Call March 02, 2023 08:30 A.M. ET Company Participants Nancy Lurker - CEO George O. Elston - CFO Jay Duker - President and COO Scott Jones - Chief Commercial Officer Conference Call Participant...
EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock fell ~8% on Thursday after the company reported its Q4 results. Net loss widened to -$43.45M, compared to -$19.43M in Q4 2021. Meanwhile, total revenue in Q4 declined -8.7% Y/Y to $10.53M, but did manage to beat analysts expectat...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...